This study is exploring a new treatment for Triple Negative Breast Cancer (TNBC), which is a type of breast cancer that does not have three common receptors known to fuel most breast cancer growth. The study involves a personalized vaccine made from a patient's own tumor to help the immune system remember and fight the cancer. It is tested alone and with medicines called checkpoint inhibitors (like pembrolizumab or ipilimumab), which help the immune system attack cancer cells better.
- Duration: The study has two phases. Phase Ia lasts for approximately 5 weeks, and Phase Ib can extend up to 9 cycles (each cycle is 21 days).
- Visits: Participants will receive treatments at specified intervals and be monitored every 12 weeks for up to 2 years after treatments.
- Risks: Potential side effects include those related to vaccines and checkpoint inhibitors, like skin reactions or immune-related symptoms.
Participants must be at least 18 years old, with a certain health status, and no severe heart, lung, or immune system conditions. This study could help in advancing cancer treatment by using personalized approaches to stimulate the immune system.
How understandable was the trial content above?
Hard to understand
Easy to understand